恶性机械性肠梗阻并发脓毒症的危险因素分析

doi:10.16689/j.cnki.cn11-9349/r.2020.03.018

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (460 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the risk factors of sepsis in cancerous mechanical bowel obstruction. Methods The clinical data of 245 patients with the first cancerous mechanical bowel obstruction were analyzed retrospectively. The possible risk factors of sepsis in these patients were analyzed by unconditional logistic regression. Results The incidence of cancerous mechanical intestinal obstruction complicated with sepsis was 11.8% (29/245). Single factor analysis suggests that concurrent sepsis may be related to the patients body mass index<18.5kg/m2(P=0.033), PG-SGA evaluation of C grade(P=0.026), and serum levels of inflammatory factors such as blood C-reactive protein, procalcitonin, interleukin-6 levels increased (P<0.05), and no glucocorticoid treatment(P=0.039), the history of abdominal and pelvic radiotherapy (P=0.001). The results of multivariate analysis showed that body mass index<18.5kg/m2, PG-SGA evaluation of C grade and serum C-reactive protein, procalcitonin, and interleukin-6 levels increased, as well as no glucocorticoid treatment and the history of abdominal pelvic radiotherapy are cancerous mechanical bowel independent risk factors for obstruction complicated with sepsis (P<0.05). Conclusion Cancerous mechanical bowel obstruction complicated with sepsis is caused by many factors, The main risk factors were patients with body mass index<18.5kg/m2, PG-SGA grade C, serum C-reactive protein, procalcitonin, interleukin-6 levels increased, glucocorticoid-free treatment and history of abdominal pelvic radiotherapy.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Liu Xing
	Zhang Wei
	Ma Huaixing
	Yu Haobin
	Wu Dan
	Liu Weiwei
	Li Shiwei
	Li Suyi

Cite this article:

Liu Xing,Zhang Wei,Ma Huaixing, et al. Analysis of risk factors of sepsis in cancerous mechanical bowel obstruction[J]. Electron J Metab Nutr Cancer, 2020, 7(3): 347-351.

URL:

http://182.92.200.144/EN/10.16689/j.cnki.cn11-9349/r.2020.03.018 OR http://182.92.200.144/EN/Y2020/V7/I3/347

1.ZELEK L, LAVAL G, ASSELAIN B. Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis［J］. J Clin Oncol, 2013, 31(19):2519-2520.
2.SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)［J］. JAMA, 2016, 315(8):801-810.
3.PLACHOURAS D, MONNET D L, CATCHPOLE M. Severe Ebola virus infection complicated by gram-negative septicemia［J］. N Engl J Med, 2015, 372(14):1376-1377.
4.李苏宜, 石汉平. 恶性肠梗阻诊断治疗的临床路径［J］. 肿瘤代谢与营养电子杂志, 2014, 1(3):27-30.
5.WU M, LIAN X J, JIA J M, et al. The role of the Patient-Generated Subjective Global Assessment (PG-SGA) and biochemical markers in predicting anemia patients with cancer［J］. Support Care Cancer, 2019, 27(4):1443-1448.
6.WIEGERT E, PADILHA P C, PERES W. Performance of Patient-Generated Subjective Global Assessment (PG-SGA) in patients with advanced cancer in palliative care［J］. Nutr Clin Pract, 2017, 32(5):675-681.
7.BALAKRISHNAN V S. Low BMI linked to worse colorectal cancer outcomes［J］. Lancet Oncol, 2015, 16(16):e593.
8.KOWALSKI G, ADO D, GAWRYCHOWSKI J. Diverticulosis of the proximal part of the jejunum causing intestinal obstruction-case report［J］. Wiad Lek, 2017, 70(6 pt 1):1146-1150.
9.CAPELA T, SOUSA P, CALDEIRA A, et al. Intestinal obstruction of uncommon cause and point-of-care ultrasonography-where do we stand?［J］. GE Port J Gastroenterol, 2018, 25(1):38-41.
10.YANG S, LI S, YU H, et al. Metronomic chemotherapy with 5-fluorouracil and cisplatin for inoperable malignant bowel obstruction because of peritoneal dissemination from gastric cancer［J］. Curr Oncol, 2016, 23(3):e248-e252.
11.KAUKONEN K M, BAILEY M, SUZUKI S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012［J］. JAMA, 2014, 311(13):1308-1316.
12.ZHANG Z, HONG Y, LIU N, et al. Association of do-not-resuscitate order and survival in patients with severe sepsis and/or septic shock［J］. Intensive Care Med, 2017, 43(5):715-717.
13.OZ H S, YEH S L, AMEDEI A. Gut inflammatory diseases, infection, and nutrition［J］. Mediators Inflamm, 2018, 2018:7160859.
14.DOBNER J, KASER S. Body mass index and the risk of infection-from underweight to obesity［J］. Clin Microbiol Infect, 2018, 24(1):24-28.
15.HAMILTON-REEVES J M, BECHTEL M D, HAND L K, et al. Effects of immunonutrition for cystectomy on immune response and infection rates: a pilot randomized controlled clinical trial［J］. Eur Urol, 2016, 69(3):389-392.
16.SU L, FENG L, SONG Q, et al. Diagnostic value of dynamics serum sCD163, sTREM-1, PCT, and CRP in differentiating sepsis, severity assessment, and prognostic prediction［J］. Mediators Inflamm, 2013, 2013:969875.
17.CAIRONI P, TOGNONI G, MASSON S, et al. Albumin replacement in patients with severe sepsis or septic shock［J］. N Engl J Med, 2014, 370(15):1412-1421.
18.CAREY T S, KINLAW A. Review: In primary care, CRP testing, shared decision making, and procalcitonin reduce antibiotic prescribing for ARI［J］. Ann Intern Med, 2018, 168(2):C11.
19.ZAHN D, HERPERTZ S, ALBUS C, et al. hs-CRP predicts improvement in depression in patients with type 1 diabetes and major depression undergoing depression treatment: results from the diabetes and depression (DAD) study［J］. Diabetes Care, 2016, 39(10):e171-e173.
20.FATTAH M A, OMER A F, ASAIF S, et al. Utility of cytokine, adhesion molecule and acute phase proteins in early diagnosis of neonatal sepsis［J］. J Nat Sci Biol Med, 2017, 8(1):32-39.
21.RUIZ-ALVAREZ M J, GARCA-VALDECASAS S, De PABLO R, et al. Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis［J］. J Intensive Care Med, 2009, 24(1):63-71.
22.SPELLBERG B, GAFFIN N. Procalcitonin-guided antibiotic use［J］. N Engl J Med, 2018, 379(20):1972-1973.
23.FAN Y, YU J L. Umbilical blood biomarkers for predicting early-onset neonatal sepsis［J］. World J Pediatr, 2012, 8(2):101-108.
24.LERCH M, MAINETTI C, TERZIROLI B B, et al. Current perspectives on erythema multiforme［J］. Clin Rev Allergy Immunol, 2018, 54(1):177-184.
25.JONES S A, JENKINS B J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer［J］. Nat Rev Immunol, 2018, 18(12):773-789.
26.COVARRUBIAS A J, HORNG T. IL-6 strikes a balance in metabolic inflammation［J］. Cell Metab, 2014, 19(6):898-899.
27.LIMAYE A P, STAPLETON R D, PENG L, et al. Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial［J］. JAMA, 2017, 318(8):731-740.
28.KOPCHICK J J, BERRYMAN D E, PURI V, et al. The effects of growth hormone on adipose tissue: old observations, new mechanisms［J］. Nat Rev Endocrinol, 2020, 16(3):135-146.
29.VENKATESH B, FINFER S, COHEN J, et al. Adjunctive glucocorticoid therapy in patients with septic shock［J］. N Engl J Med, 2018, 378(9):797-808.
30.莫佳丽, 解基良, 张楠. 肠道菌群与肠梗阻关系的研究进展［J］. 中国中西医结合外科杂志, 2020,26(4): 783-787.
31.NAKATA K, FUKUNAGA M, EBIHARA T, et al. A study of laparoscopic stoma creation for patients with malignant bowel obstruction［J］. Gan To Kagaku Ryoho, 2013, 40(12):1702-1704.
32.MASSACESI C, GALEAZZI G. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction［J］. Palliat Med, 2006, 20(7):715-716.